List view / Grid view

Immuno-oncology therapeutics

Filter the results

 

article

Immuno-oncology In-Depth Focus 2020

26 May 2020 | By

This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.

article

Drug Target Review – Issue 2 2020

26 May 2020 | By

In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.

article

TCR therapy – an attractive alternative to CAR T

24 March 2020 | By

Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…